These are types of brain and spinal cord tumors that start from cells called neuroepithelial cells. These cells are the building blocks of the nervous system and can develop into different types of nerve cells, like neurons or support cells. Most tumors in the brain and spinal cord are of this type.
Every report comes from a Lived member, sent anonymously.
Have you had Craniotomy for Neuroepithelial Tumors?
Neuroepithelial tumors are growths that start in the brain or spinal cord from the cells that build the nervous system. These cells can develop into neurons, which carry nerve signals, or into glial cells such as astrocytes and oligodendrocytes, which support and protect neurons. Because they begin in the brain or spinal cord itself, they are primary tumors, unlike cancer that has spread there from another part of the body. The name is an umbrella term for a large family rather than a single disease. Its biggest group is the gliomas, which include astrocytomas, oligodendrogliomas, ependymomas and glioblastoma. The family also includes tumors made of nerve cells or a mix of nerve and glial cells, tumors of the pineal gland, and embryonal tumors such as medulloblastoma, which mostly affects children and young adults. Some of these tumors grow slowly and may be removed completely with surgery; others grow quickly into the surrounding brain. The specific type, its grade and its location say far more about what lies ahead than the family name does. Symptoms come from the tumor pressing on or growing into the part of the brain or spinal cord around it, so they depend on where it is and how large it has become. Common ones include headaches (often worse in the morning or easing after vomiting), seizures, nausea, changes in personality, mood, memory or concentration, weakness, and problems with vision, speech, hearing or balance. Tumors in the spinal cord more often cause back pain that spreads toward the arms or legs, numbness or weakness in the limbs, and changes in bladder or bowel control. Symptoms may develop slowly, and each of them is more often caused by something other than a tumor.
For most people, no cause is ever found. Tumors form when changes build up in the genes that control how cells grow and divide, and in most cases those changes happen by chance during a person's life rather than being inherited. Apart from radiation, no diet, habit or everyday environmental exposure has been clearly linked to these tumors. Radiation to the head, most often radiation therapy given for another cancer such as childhood leukemia, is the one well-established outside risk factor. Tumors linked to radiation usually appear 10 to 15 years later, sometimes decades later, and they are rare; for people who need radiation to treat a cancer, the benefit usually far outweighs this later risk. Imaging tests such as CT scans use much lower doses, and any added risk from them is likely very small. A small share of tumors occur as part of inherited syndromes that raise the risk of several tumor types, including neurofibromatosis type 1 and type 2, tuberous sclerosis, Li-Fraumeni syndrome and Turcot syndrome. Most people with these tumors have no family history of them. Overall risk rises with age, although some types, such as medulloblastoma, occur mainly in children and young adults.
Assessment starts with a neurological exam, which checks thinking, coordination, walking, strength, reflexes, vision and other nerve functions to show which part of the nervous system may be affected. The main imaging test is MRI (magnetic resonance imaging), usually with an injected contrast dye called gadolinium that makes tumor tissue show up more brightly. A CT (computed tomography) scan may also be used. Imaging shows a tumor's size and position, but it usually cannot say exactly what kind of tumor it is. That normally takes a tissue sample, removed during surgery or through a biopsy, in which a needle guided by 3D imaging is passed through a small opening in the skull. Occasionally a biopsy is not safe because of where the tumor sits, and doctors rely on the imaging and the overall picture instead. A pathologist then names the tumor type and gives it a grade from 1 to 4. Lower grades look more like normal cells and grow slowly; grade 3 and 4 tumors look very abnormal and grow faster, with glioblastoma at grade 4. Since the World Health Organization's 2021 classification, the diagnosis also depends on testing the tumor's genes. For gliomas, results such as a change in the IDH1 or IDH2 gene (which make an enzyme called isocitrate dehydrogenase, or IDH), the loss of parts of chromosomes 1p and 19q, and whether the MGMT gene, which helps tumor cells repair DNA damage, has been switched off (called MGMT methylation) help predict how the tumor will behave and guide treatment. The final report combines how the cells look with these genetic features.
Treatment depends on the tumor's type, grade, genetic features and location, whether it has just been found or has come back, and the person's age and overall health. A plan often combines several of the approaches below. Surgery is usually the first step when it can be done safely. Removing tumor tissue relieves pressure on the surrounding brain and supplies tissue for diagnosis, and some grade 1 tumors can be removed completely. Surgeons aim to take out as much as they safely can, so when a tumor lies close to areas that control movement, speech or other essential functions, some may be left behind. Radiation therapy and chemotherapy treat tumor cells that remain after surgery or tumors that cannot be removed. For newly diagnosed glioblastoma, a common approach after surgery is radiation given together with temozolomide, a chemotherapy pill, followed by temozolomide on its own as maintenance treatment. Radiation to the brain can affect memory and thinking over time, which is one reason it is planned carefully and repeated only after weighing the risks. Targeted medicines act on a specific feature of the tumor. Vorasidenib (Voranigo), a daily pill that blocks the abnormal IDH enzyme, is approved for people 12 and older with a grade 2 astrocytoma or oligodendroglioma that carries an IDH1 or IDH2 mutation, after surgery or biopsy. In the trial that led to its approval, people who had not yet had radiation or chemotherapy went longer before their tumor grew than people taking a placebo. It needs regular liver blood tests and can harm a developing baby. Bevacizumab (Avastin), an infused antibody that blocks the growth of new blood vessels that tumors depend on, is used for glioblastoma that has come back; it can help some people reduce or stop steroids, but studies disagree on whether it improves quality of life. For some very slow-growing tumors that cause no symptoms, active surveillance (regular scans without immediate treatment) can delay or avoid the side effects of surgery or radiation. Supportive care runs alongside every option: a steroid such as dexamethasone reduces swelling around the tumor, and antiseizure medicines are used for anyone who has had a seizure. Proton beam radiation and immunotherapy are being studied in clinical trials, which people can join before, during or after standard treatment. Treatment for children is sometimes different from treatment for adults, and its long-term effects weigh heavily in those choices.
The outlook varies widely across this family. A grade 1 tumor that is fully removed may need nothing more than follow-up scans. Grade 2 tumors grow slowly but can come back, and some later change into a higher-grade tumor, so they need long-term monitoring. High-grade tumors, including glioblastoma, grow quickly and are more likely to return after treatment, and care then focuses on controlling the tumor, managing symptoms and protecting quality of life. Beyond type and grade, outlook depends on where the tumor is, how much could be removed, its genetic changes and the person's general health, so the care team is the best source for an individual estimate. Daily life is shaped by where the tumor is and what treatment involves. Some people have lasting changes in strength, speech, vision, memory or mood, and seizures may need ongoing medicine. Changes in thinking or personality can be especially hard for families, and support for caregivers is worth arranging early. Follow-up continues after treatment ends. MRI scans and checkups are repeated over time to see whether the tumor has changed or come back, and results guide whether to continue, change or stop treatment. For children, long-term effects of treatment on learning, growth and development are an important part of follow-up.
See a doctor about headaches that feel different from your usual ones or keep getting worse, especially with persistent nausea, vomiting or drowsiness, and about gradual changes in memory, personality, vision, speech, balance or strength on one side of the body. Back pain that spreads into the arms or legs with numbness, weakness or new bladder or bowel problems also needs assessment. Most of these symptoms turn out to have other causes, but they should be checked. If you are being treated for a tumor, report any seizure to your care team, along with new or worsening symptoms between appointments. Call 911 if someone has a seizure for the first time, if a seizure lasts longer than 5 minutes, or if seizures follow one another without the person waking up in between.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Neuroepithelial Tumors is like, what's helped you, or ask the community a question.